Zydus Cadila completes large scale enrolment for two Phase III trials of Desidustat

05 Feb 2021 Evaluate

Zydus Cadila has completed patient enrolment in DREAM-ND and DREAM-D Phase III trials of Desidustat, an oral small molecule hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor for treatment of anaemia in patients with Chronic Kidney Disease (CKD).

The DREAM-ND Phase III trial has now enrolled 588 CKD patients not-on-dialysis. This Phase II study is a multicentre (68 sites), randomized, active-controlled clinical trial to evaluate the efficacy and safety of Desidustat versus Darbepoetin for the treatment of anaemia in patients with chronic kidney disease (CKD) who are not on dialysis.

Cadila Healthcare is an India-based pharmaceutical company. The company's subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.

Zydus Lifesciences Share Price

919.55 -16.75 (-1.79%)
19-Apr-2024 14:16 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1516.95
Dr. Reddys Lab 5928.80
Cipla 1353.55
Zydus Lifesciences 919.55
Lupin 1555.65
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.